Benzinga | Jan 20, 2021 06:42AM EST

Baird Downgrades Gritstone Oncology to Underperform, Announces $8 Price Target

Baird analyst Madhu Kumar downgrades Gritstone Oncology (NASDAQ:GRTS) from Outperform to Underperform and announces $8 price target.